Distributor inventory | Tablet

Type 2 diabetes mellitus: to improve blood sugar control in adults when diet and exercise alone or single-drug therapy is inadequate

Vildagliptin is a DPP-4 inhibitor that increases incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin release and reducing glucagon. Metformin reduces glucose production by the liver and improves insulin sensitivity, lowering blood sugar levels.

Oral tablet. Take exactly as prescribed, usually with meals to reduce stomach upset. Swallow whole with water; do not crush/chew if it is SR/ER. Regularly monitor blood glucose; follow diet and exercise advice.

Nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, headache, dizziness, upper respiratory tract infection, low blood sugar (especially with insulin/sulfonylureas)

Not for type 1 diabetes or diabetic ketoacidosis. Metformin may rarely cause lactic acidosis—risk increases with kidney disease, dehydration, heavy alcohol use, severe infection, liver disease, heart failure, and advanced age; kidney function should be assessed before and during treatment. Stop temporarily before/after iodinated contrast imaging or major surgery as advised. Monitor for pancreatitis symptoms (severe abdominal pain), hypersensitivity/skin reactions, and vitamin B12 deficiency with long-term use. Use caution in elderly and in patients with renal/hepatic impairment.

Alcohol, iodinated contrast media, carbonic anhydrase inhibitors (e.g., topiramate, acetazolamide), insulin/sulfonylureas (increased hypoglycaemia risk), cimetidine (may increase metformin levels), diuretics and ACE inhibitors (may affect kidney function), corticosteroids and beta-agonists (may raise glucose), quinolones (may alter glucose control)

Store below 25°C, in a dry place protected from moisture and light. Keep in original blister pack and out of reach of children.

Galvus Met 50/500 Tablet, Zomelis Met 50/500 Tablet, Jalra-M 50/500 Tablet, Vildamet 50/500 Tablet, Vilda-M 50/500 Tablet